- Menopause
There is a menopause symptom that affects more women than hot flashes and that far fewer women talk about, report to their clinicians, or receive treatment for.
It involves the tissue changes that occur in the vulva, vagina, and urinary tract in the absence of estrogen. It can cause discomfort or pain during intercourse, vaginal dryness, burning, increased urinary urgency or frequency, and recurrent urinary tract infections. For some women, it develops gradually over years. For others, it arrives more acutely.
It is called the genitourinary syndrome of menopause (GSM) and it is not a minor inconvenience or an inevitable feature of aging. It is a physiologically coherent, well-understood condition with effective treatments that some women have never been told exist.
The vulva, vagina, and lower urinary tract are among the most estrogen-sensitive tissues in the body. Throughout reproductive life, estrogen maintains the thickness, elasticity, and lubrication of vaginal tissue. It supports the health of the cells lining the vaginal wall, maintains an acidic vaginal pH (which provides natural protection against infection), and supports the tone and function of the pelvic floor and urinary structures.
After menopause, circulating estrogen drops substantially. Without that hormonal support, these tissues undergo changes that are gradual but cumulative:
Vaginal tissue changes. The vaginal walls thin and lose rugae — the folds and elasticity that allow for expansion. The tissue becomes more fragile and less well-lubricated. Blood flow to the vaginal tissue decreases. These changes can develop slowly over years and may not be significant initially, but they progress over time in the absence of estrogen or treatment.
pH changes. The vaginal environment becomes less acidic as estrogen-dependent lactobacillus populations decline. This shift in pH increases susceptibility to bacterial vaginosis and UTIs, which is why recurrent infections are common in post-menopause.
Urinary tract changes. The lower urinary tract, including the urethra and bladder, is similarly estrogen-dependent. Changes in these tissues contribute to urinary urgency, frequency, stress incontinence, and increased UTI frequency.
Vulvar changes. The labia minora and majora may lose tissue volume and elasticity. The clitoral hood may become less distinct. These structural changes are part of the broader tissue response to reduced estrogen.
Estimates suggest that 50 to 80 percent of post-menopausal women experience symptoms of GSM. Unlike vasomotor symptoms such as hot flashes, which tend to diminish over time for many women, GSM symptoms do not resolve on their own. Without treatment, they typically worsen gradually over time.
Despite this prevalence, GSM is dramatically underreported. Studies consistently show that the majority of affected women do not discuss these symptoms with a healthcare professional due to embarrassment or an assumption that it is simply a normal part of aging, or a belief that nothing can be done.
All three of those assumptions are incorrect.
GSM symptoms vary in character and severity. Some women experience one symptom prominently; others experience several simultaneously.
Vaginal dryness is the most commonly reported symptom — a persistent feeling of dryness that may be present at baseline or more noticeable during sexual activity.
Dyspareunia — painful intercourse — is reported by a significant proportion of post-menopausal women and is a primary driver of sexual avoidance and reduced intimacy. The pain may be characterized as burning, friction, tearing, or deep aching. It is not psychological in origin, though the psychological impact — on self-perception, relationships, and quality of life — is real.
Burning or irritation may occur independent of sexual activity and can be ongoing or intermittent.
Recurrent urinary tract infections in a woman who was not previously prone to them are a meaningful clinical signal for GSM-related urinary tract changes.
Urinary urgency or frequency — the sensation of needing to urinate frequently or suddenly — may be related to urethral and bladder tissue changes rather than to a urinary tract infection.
GSM is one of the most treatable menopause-related conditions. Treatment options range from over-the-counter measures to prescription therapies, and the right approach depends on symptom severity, the presence of contraindications, and individual preference.
Non-Hormonal Options
Vaginal moisturizers — distinct from lubricants — are applied regularly (not only during sexual activity) and help maintain vaginal tissue hydration over time. Products with hyaluronic acid have good evidence for symptom relief. Regular use is key; they work cumulatively rather than immediately.
Lubricants used during sexual activity reduce friction and discomfort acutely. Water-based and silicone-based lubricants are both effective; oil-based products also are effective however should be avoided with latex. These address the immediate symptoms but do not address the underlying tissue change.
Regular sexual activity supports vaginal blood flow and tissue health. This is physiologically meaningful, not merely anecdotal.
Local Vaginal Estrogen
Local vaginal estrogen — delivered as a cream, suppository, tablet, or ring — acts directly on vaginal and urethral tissue with minimal systemic absorption. It addresses the underlying tissue changes rather than managing symptoms around them.
It is highly effective. Studies consistently show significant improvement in vaginal tissue health, pH, symptom scores, and quality of life. It is generally well-tolerated and can be used long-term.
Importantly, local vaginal estrogen may be considered appropriate for many women who are not candidates for systemic hormone therapy. For women who have survived breast cancer, this is a nuance worth discussing with a clinician, as individual circumstances vary.
A newer option, ospemifene, is an oral medication that acts on vaginal tissue as an estrogen agonist and is an option for women who prefer an oral route.
DHEA (prasterone) vaginal suppositories are another option that works locally and has good evidence for dyspareunia specifically. These options are provided as education to help start a conversation with your care team if interested.
Systemic Hormone Therapy
For women who also have vasomotor symptoms or other indications for systemic hormone therapy, systemic therapy will also address GSM — though local therapy is often the preferred approach when GSM is the primary concern.
Many of the symptoms of GSM overlap with other conditions. Recurrent UTIs may be related to other factors. Urinary urgency has multiple causes. Vulvar pain has a differential diagnosis. An accurate diagnosis matters for appropriate treatment.
Additionally, some women have conditions — such as a history of certain hormone-sensitive cancers — that affect the risk-benefit calculation for hormonal treatment. The decision about which treatment approach is most appropriate requires individual clinical assessment.
If you are experiencing symptoms consistent with GSM, bring them to a clinical appointment explicitly. Since these symptoms are underreported, they are often not screened for proactively. Naming them directly, “I have noticed vaginal dryness, discomfort during sex, and increased urinary frequency since my periods stopped” is the most reliable way to ensure they are addressed.
You do not need to manage these symptoms in silence. Effective treatment exists and most women respond well to it.
The MyClarity Menopause learning path covers the genitourinary syndrome of menopause in depth — including the physiology of tissue changes, the full range of treatment options, and the clinical language to use in a conversation with your provider. It is one of the most underserved topics in post-menopausal health education, and one of the areas where understanding the physiology most directly translates into better quality of life.
Learn more about the MyClarity Menopause learning path
Download the free Menopause MyCare Conversation Guide
If you liked this consider reading a supportive article here.
April Lind, MD is a physician and the founder of MyClarity, a women’s health education platform. This article is for educational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for individual assessment and treatment.
Dr. April Lind, Founder of MyClarity
As a physician in women’s health, I have spent years caring for women across life stages – adolescence, pregnancy, postpartum, infertility and into midlife. I created MyClarity because women deserve to understand what is happening in their bodies before they are told what to do about it.
Join my mailing list and receive new posts directly to your inbox.
